AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$NKTR

Zalevsky Jonathan sold $398K of NKTR

Zalevsky Jonathan (Chief R&D Officer) sold 5,681 shares of NEKTAR THERAPEUTICS (NKTR) at $70.00 ($0.40M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zalevsky Jonathan
Published Jul 2, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
high confidence
Mentioned
$NKTR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale details (shares, price, total value) executed under a pre-arranged 10b5-1 plan; no other company-specific news is provided.

02

Market read

Traders may note insider selling, but 10b5-1 structure and lack of new fundamentals make it low-impact.

03

What to watch

The filing doesn’t state net proceeds use, tax context, or whether other insiders/large holders acted—so the signal is inherently limited.

Relevance 3/10Novelty 5/10Timing: filed after-hours on 2026-07-02; reflects sale executed 2026-06-30

Background

The article is an SEC Form 4 insider transaction disclosure for NeKTAR Therapeutics (NKTR).

Company-level read

Ticker impact

$NKTRNeutralHigh confidence
Context

SEC Form 4 shows Chief R&D Officer Jonathan Zalevsky sold 5,681 NKTR shares at $70 on 2026-06-30 under a 10b5-1 plan.

Expected impact

Minimal near-term impact; any effect is likely short-lived and outweighed by normal trading/positioning.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by an officer, with no accompanying new operational, regulatory, or financial catalyst in the text.

Market effects

Sector

No sector read-through; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    NEKTAR THERAPEUTICS

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Zalevsky Jonathan

    Chief R&D Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

AUG 31
$NKTRLow

Rezpegaldesleukin Shows Promise in Atopic Dermatitis

Rezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.

medscape.com2 min
AUG 28
$NKTRMedAI 8/10

Dollar Balance Sheet Faces a Multi

Nektar Therapeutics (NKTR) reported Q2 2026 results showing increased cash and investments ($1.02B) due to equity raises, but still no commercial revenue. Net loss was $40.6M, down slightly from Q2 2025. The company's focus is on advancing its pipeline, particularly REZPEG, with management emphasizing clinical progress over near-term solvency.

news.alphastreet.com3 min
AUG 27
$NKTRMedAI 8/10

Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test

Nektar Therapeutics (NKTR) reported Q2 earnings, highlighting a $1.02B cash balance and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The company expects top-line data in mid-2028 and a potential Biologics License Application submission in 2029. NKTR's operating loss widened to $42.3M, with R&D spending expected to increase. The company raised $373.8M in April 2026 to fund operations.

yahoo.com3 min
AUG 21
$NKTRMedAI 8/10

Nektar (NKTR) Q2 2026 Earnings Call Transcript

Nektar Therapeutics reported Q2 2026 earnings with noncash royalty revenue of $10.1M, a net loss of $40.6M, and cash/investments of $1.02B. The company initiated Phase 3 trials for rezpegaldesleukin and updated full-year guidance, including revenue of $40M-$45M and end-of-year cash of $815M-$840M. Management expects a cash runway into Q3 2028, supported by a recent public offering.

fool.com3 min